Patents by Inventor Michael Mayersohn

Michael Mayersohn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240024254
    Abstract: Provided herein are transdermal delivery devices comprising ketamine, such as monolithic transdermal patches. Also provided herein are methods of preparing transdermal delivery devices. The transdermal delivery device and monolithic patch herein can have various uses, for example, for treating various diseases or disorders, such as depression, anxiety, and/or pain in a subject in need thereof.
    Type: Application
    Filed: January 17, 2023
    Publication date: January 25, 2024
    Inventors: Huadong TANG, Hock S. TAN, Michael MAYERSOHN, Wenfei LIANG
  • Patent number: 11559497
    Abstract: Provided herein are transdermal delivery devices comprising ketamine, such as monolithic transdermal patches. Also provided herein are methods of preparing transdermal delivery devices. The transdermal delivery device and monolithic patch herein can have various uses, for example, for treating various diseases or disorders, such as depression, anxiety, and/or pain in a subject in need thereof.
    Type: Grant
    Filed: June 18, 2021
    Date of Patent: January 24, 2023
    Assignee: GUANGZHOU DAZHOU BIOMEDICINE LTD.
    Inventors: Huadong Tang, Hock S. Tan, Michael Mayersohn, Wenfei Liang
  • Publication number: 20220395469
    Abstract: Provided herein are ketamine gel formulations, transdermal delivery devices comprising ketamine, methods of preparation and methods of using thereof. The transdermal delivery device can be a drug-in-reservoir (DIR) patch comprising ketamine, which typically includes a backing layer, a reservoir layer comprising a ketamine gel formulation, a rate-controlling membrane, an adhesive layer, and a release liner. The ketamine gel formulation generally includes one or more skin permeation enhancers. The transdermal delivery devices can be configured, for example, by adjusting the ketamine gel formulation and other release control mechanism, to provide certain skin flux characteristics, and can be used for treating a variety of indications such as depression and/or pain.
    Type: Application
    Filed: June 13, 2022
    Publication date: December 15, 2022
    Inventors: Huadong TANG, Hock S. TAN, Michael MAYERSOHN
  • Publication number: 20220193000
    Abstract: The present invention is directed to a transdermal delivery device comprising ketamine and formulations thereof. The present invention is also directed to a transdermal delivery device comprising ketamine for the treatment of major depressive disorder (MDD) and/or pain. The present invention is further directed to a transdermal delivery device comprising ketamine and abuse deterrent agents.
    Type: Application
    Filed: December 2, 2021
    Publication date: June 23, 2022
    Inventors: Huadong TANG, Hock S. TAN, Michael MAYERSOHN
  • Publication number: 20210393544
    Abstract: Provided herein are transdermal delivery devices comprising ketamine, such as monolithic transdermal patches. Also provided herein are methods of preparing transdermal delivery devices. The transdermal delivery device and monolithic patch herein can have various uses, for example, for treating various diseases or disorders, such as depression, anxiety, and/or pain in a subject in need thereof.
    Type: Application
    Filed: June 18, 2021
    Publication date: December 23, 2021
    Inventors: Huadong TANG, Hock S. TAN, Michael MAYERSOHN, Wenfei LIANG
  • Patent number: 11191734
    Abstract: The present invention is directed to a transdermal delivery device comprising ketamine and formulations thereof. The present invention is also directed to a transdermal delivery device comprising ketamine for the treatment of major depressive disorder (MDD) and/or pain. The present invention is further directed to a transdermal delivery device comprising ketamine and abuse deterrent agents.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: December 7, 2021
    Assignee: SHENOX PHARMACEUTICALS, LLC
    Inventors: Huadong Tang, Hock S. Tan, Michael Mayersohn
  • Publication number: 20210308040
    Abstract: Provided herein are film compositions comprising ketamine suitable for delivering ketamine across oral mucosal membranes. The film compositions can have various designs such as quick-release film, slow-release film, bilayer film that combines both a quick-release and slow-release film, or one-directional release film. Further are included methods of using the film compositions herein for the treatment of various diseases or disorders, such as pain and/or depression.
    Type: Application
    Filed: October 23, 2019
    Publication date: October 7, 2021
    Inventors: Hock S. TAN, Huadong TANG, Michael MAYERSOHN, Wenfei LIANG
  • Publication number: 20200030251
    Abstract: Provided herein are ketamine gel formulations, transdermal delivery devices comprising ketamine, methods of preparation and methods of using thereof. The transdermal delivery device can be a drug-in-reservoir (DIR) patch comprising ketamine, which typically includes a backing layer, a reservoir layer comprising a ketamine gel formulation, a rate-controlling membrane, an adhesive layer, and a release liner. The ketamine gel formulation generally includes one or more skin permeation enhancers. The transdermal delivery devices can be configured, for example, by adjusting the ketamine gel formulation and other release control mechanisms, to provide certain skin flux characteristics, and can be used for treating a variety of indications such as depression and/or pain.
    Type: Application
    Filed: April 19, 2018
    Publication date: January 30, 2020
    Inventors: Huadong TANG, Hock S. TAN, Michael MAYERSOHN
  • Publication number: 20180353437
    Abstract: The present invention is directed to a transdermal delivery device comprising ketamine and formulations thereof. The present invention is also directed to a transdermal delivery device comprising ketamine for the treatment of major depressive disorder (MDD) and/or pain. The present invention is further directed to a transdermal delivery device comprising ketamine and abuse deterrent agents.
    Type: Application
    Filed: June 27, 2016
    Publication date: December 13, 2018
    Inventors: Huadong Tang, Hock S. Tan, Michael Mayersohn